Cullinan Therapeutics reported a net loss of $70.1 million for Q2 2025, an increase from $42.0 million in Q2 2024, primarily driven by a significant rise in research and development expenses to $61.0 million. The company maintained a strong cash position of $510.9 million, providing a runway into 2028.

Cullinan Therapeutics reported a net loss of $48.501 million for Q1 2025, an increase from the $37.340 million net loss in Q1 2024. Research and development expenses increased significantly, while interest income also saw a rise.

Cullinan Therapeutics reported its Q4 and full year 2024 financial results, highlighting key updates for CLN-978 and zipalertinib. The pivotal Phase 2b study for zipalertinib met its primary endpoint, with NDA submission planned for H2 2025. The company's cash and investments totaled $606.9 million, providing runway into 2028.

Cullinan Therapeutics reported a net loss of $40.6 million for the third quarter of 2024. The company's cash, cash equivalents, short- and long-term investments, and interest receivable were $639.0 million as of September 30, 2024, which is expected to provide runway into 2028.

Cullinan Therapeutics reported a net loss of $42.0 million for the second quarter of 2024, with cash, cash equivalents, investments, and interest receivable totaling $664.9 million as of June 30, 2024. The company is advancing its pipeline, including CLN-978 for autoimmune diseases and CLN-619 for oncology, and expects its cash resources to provide runway into 2028.

Cullinan Therapeutics reported its first quarter 2024 financial results, highlighting a strategic expansion into immunology with CLN-978, advancements in oncology programs, and a strong cash position extended into 2028 with a recent private placement. The company also appointed David Meek to its Board of Directors.

Cullinan Oncology reported a net loss of $25.6 million for the fourth quarter of 2023, with cash, cash equivalents, investments, and interest receivable totaling $468.3 million as of December 31, 2023. The company's cash resources are expected to provide runway into the second half of 2026. They also remain on track to report additional solid tumor dose escalation data for CLN-619 in Q2 2024 and received FDA clearance for an IND to evaluate CLN-619 in relapsed/refractory multiple myeloma.

Cullinan Oncology reported a net loss of $39.2 million for the third quarter of 2023. As of September 30, 2023, the company's cash and investment position was $482 million, expected to provide runway into the second half of 2026.

Cullinan Oncology reported a cash and investment position of $512.1 million as of June 30, 2023, which is expected to provide runway into 2026. The company also announced the initiation of a Phase 3 study of zipalertinib and presented initial clinical monotherapy data for CLN-619 at ASCO 2023.

Cullinan Oncology reported a net loss of $58.1 million for the first quarter of 2023. The company's cash and investment position was $503.5 million as of March 31, 2023, expected to provide runway into 2026. Enrollment in the zipalertinib pivotal study will now continue at the 100mg BID dose only.

Cullinan Oncology reported a net loss of $27.1 million for the fourth quarter of 2022, with cash and investments totaling $550.1 million as of December 31, 2022, which provides runway into 2026.

Cullinan Oncology reported cash and investments of approximately $607 million as of September 30, 2022. The company is focused on advancing its pipeline and strategically deploying capital for investment, acceleration, and expansion.

Cullinan Oncology reported a net income of $174.1 million for the second quarter of 2022, driven by a $275 million upfront payment from the sale of Cullinan Pearl. The company's cash and investments were $656 million as of June 30, 2022, expected to fund operations through 2026.

Cullinan Oncology reported its Q1 2022 financial results, highlighting a cash position of $685 million, including an upfront payment from the Taiho collaboration, expected to provide runway through 2026. The company also made progress in advancing its pipeline, including CLN-081, CLN-049, and CLN-619.

Cullinan Oncology reported its fourth quarter and full year 2021 financial results. Clinical trials for CLN-619 and CLN-049 were initiated, and an HPK1 degrader collaboration with Mount Sinai was established. The company finished the year with over $430 million in cash and investments.

Cullinan Oncology reported a net loss of $18.3 million and held $445.4 million in cash, cash equivalents, and investments as of September 30, 2021. The company is advancing its pipeline, with clinical updates for Cullinan Pearl expected in Q4 2021 and plans to advance Cullinan MICA and Cullinan Florentine into clinical trials by year-end.

Cullinan Oncology reported a strong cash position of $456.3 million as of June 30, 2021, and highlighted the IND clearance of two immuno-oncology pipeline programs, Cullinan MICA and Cullinan Florentine. Interim data from the Cullinan Pearl trial showed a disease control rate of 92% in the 100mg dose cohort.

Cullinan Oncology reported a net income of $1.4 million for Q1 2021, which included $18.9 million in revenue from a license agreement with Zai Lab. The company's cash, cash equivalents, and investments totaled $473.0 million as of March 31, 2021.

Cullinan Oncology reported its full year 2020 financial results, highlighting pipeline advancements, a strengthened balance sheet through Series C financing and an IPO, and key team expansions.